Healthcare >> CEO Interviews >> November 1, 2002
ROBERT A. INGRAM, Chief Operating Officer and President of
Pharmaceutical Operations at GlaxoSmithKline Plc, assumed those
roles in January 2001. He is a member of the Corporate Executive
Team. He began his career in the pharmaceutical industry as a
sales representative for the company that would later become
Merrell Dow Pharmaceuticals. He advanced rapidly through sales
management at Merrell Dow and into government and public affairs.
He left Merrell Dow in 1985 as Vice President of Public Affairs
to become Vice President of Government Affairs at Merck & Co.
Inc. In 1988, he was promoted to President of Merck Frosst Canada
Inc. In 1990, he left Merck to join Glaxo Inc., Glaxo plc's US
subsidiary, as Executive Vice President of Administrative and
Regulatory Affairs and assumed a series of increasingly
responsible positions, including Group Vice President. He was
named Executive Vice President in January 1993, President and
Chief Operating Officer in June 1993, President and Chief
Executive Officer in March 1994, and Chairman in January 1999. As
an Executive Director of Glaxo Wellcome plc, Mr. Ingram held
responsibility for operations in North America and Latin America.
He was appointed to the global company's Board in May 1995. In
October 1997, he became Chief Executive of Glaxo Wellcome plc
with responsibility for worldwide business operations, and added
the position of Chairman to his responsibilities at Glaxo
Wellcome Inc. Mr. Ingram graduated from Eastern Illinois
University with a BS degree in Business Administration. He serves
on the Board of Directors of the Wachovia Corporation, Nortel
Networks, Lowe's Companies, Molson Inc. and Misys plc (non-
executive Director). Profile
a couple of years ago of Glaxo Wellcome and SmithKline Beecham?
Mr. Ingram: The heritage Glaxo Wellcome management team
